Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MURTAZA MUSSAJI

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1487705034
CMS profile
113159
Location
HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$5,943.92

231 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $4,667.02 227
Consulting Fee $1,200.00 1
Travel and Lodging $50.29 1
Gift $20.00 1
Education $6.61 1

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 5; records 51–100 of 231 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MURTAZA MUSSAJI

NPI 1487705034 · CMS profile ID 113159

Allopathic & Osteopathic Physicians / Internal Medicine

HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 5; records 51–100 of 231 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1487705034?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MURTAZA MUSSAJI, NPI 1487705034, CMS profile ID 113159. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 231 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1487705034?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). MURTAZA MUSSAJI, NPI 1487705034, CMS profile ID 113159. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 231 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1487705034?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
MURTAZA MUSSAJI, NPI 1487705034, CMS profile ID 113159, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 5; records 51–100 of 231 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1487705034?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

231 matching records · $5,943.92 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 231 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 231.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novo Nordisk Inc $105.3810/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810912915 CMS
Novartis Pharmaceuticals Corporation $14.3210/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813105643 CMS
Biohaven Pharmaceuticals, Inc. $14.5510/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852573557 CMS
AstraZeneca Pharmaceuticals LP $13.5810/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829514371 CMS
SANOFI-AVENTIS U.S. LLC $100.0010/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843611601 CMS
SANOFI-AVENTIS U.S. LLC $14.3010/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843611615 CMS
GlaxoSmithKline, LLC. $7.5109/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801779865 CMS
Janssen Pharmaceuticals, Inc $17.9709/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788308007 CMS
Novo Nordisk Inc $24.2509/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810872477 CMS
Teva Pharmaceuticals USA, Inc. $15.1609/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839531235 CMS
AbbVie Inc. $5.1509/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795260131 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $13.4709/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850278577 CMS
PFIZER INC. $31.2009/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832843829 CMS
Eisai Inc. $16.7009/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 817999139 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $15.2109/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763737972 CMS
Janssen Pharmaceuticals, Inc $8.7809/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788308011 CMS
Lilly USA, LLC $13.0609/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818613495 CMS
PFIZER INC. $14.5609/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833505513 CMS
AstraZeneca Pharmaceuticals LP $13.8709/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829885325 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $11.9109/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763737974 CMS
Amarin Pharma Inc. $20.8109/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815391017 CMS
Janssen Pharmaceuticals, Inc $7.6409/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788308009 CMS
Currax Pharmaceuticals LLC $14.2808/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792534695 CMS
Novo Nordisk Inc $22.5308/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811031063 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $22.7508/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763737976 CMS
Eisai Inc. $16.6508/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 817983673 CMS
Bayer HealthCare Pharmaceuticals Inc. $16.0008/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789198063 CMS
Teva Pharmaceuticals USA, Inc. $126.2508/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839531071 CMS
PFIZER INC. $13.7408/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833520845 CMS
AstraZeneca Pharmaceuticals LP $105.1808/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829757225 CMS
Currax Pharmaceuticals LLC $11.2308/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792534693 CMS
Teva Pharmaceuticals USA, Inc. $19.4008/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839531233 CMS
Janssen Pharmaceuticals, Inc $11.7308/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788308003 CMS
Kowa Pharmaceuticals America, Inc. $14.1208/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 805539675 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $12.2808/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850175627 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $1.0308/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850257041 CMS
Amarin Pharma Inc. $19.1708/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815391015 CMS
Novo Nordisk Inc $0.1408/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810991847 CMS
Novo Nordisk Inc $19.4908/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811109431 CMS
Lilly USA, LLC $10.6408/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818672225 CMS
AbbVie Inc. $20.0008/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795260119 CMS
AbbVie Inc. $16.6408/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795260125 CMS
GlaxoSmithKline, LLC. $15.9008/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802621371 CMS
GlaxoSmithKline, LLC. $0.8808/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802803181 CMS
AstraZeneca Pharmaceuticals LP $17.3808/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830272505 CMS
Horizon Therapeutics plc $15.4208/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797177415 CMS
Amarin Pharma Inc. $18.0508/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815218959 CMS
AstraZeneca Pharmaceuticals LP $13.3508/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830131309 CMS
Biohaven Pharmaceuticals, Inc. $1,200.0007/31/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852573553 CMS
Biohaven Pharmaceuticals, Inc. $50.2907/31/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852573555 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $10,376.98 265
PY2020 $4,023.40 217
PY2021 $5,943.92 231
PY2022 $8,005.12 202
PY2023 $4,382.21 194
PY2024 $3,415.48 152
PY2025 $4,572.58 146

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,487,105.15 129
PY2024 Principal investigator $1,707,171.72 156
PY2023 Principal investigator $2,187,135.32 461
PY2022 Principal investigator $2,343,599.06 547
PY2021 Principal investigator $3,285,004.06 293
PY2020 Principal investigator $1,489,147.39 62
PY2019 Recipient $73,560.68 2
PY2019 Principal investigator $513,437.41 43

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

129 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $600.00 12/31/2025 Non-covered Recipient Entity
LINQ RESEARCH LLC
A Phase 3, Multicenter, Open-Label 156-Week Extension Study To Evaluate The Long-Term Safety And Tolerability Of Oral Atogepant For The Prevention Of Migraine In Participants With Chronic Or Episodic Migraine No dispute reported 06/30/2026 1202533453
Principal investigator 1 Merck Sharp & Dohme LLC $18,497.88 12/31/2025 Non-covered Recipient Entity
LinQ Research
A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression No dispute reported 06/30/2026 1232929437
Principal investigator 1 Merck Sharp & Dohme LLC $274.40 12/31/2025 Non-covered Recipient Entity
LinQ Research
A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression No dispute reported 06/30/2026 1232929439
Principal investigator 1 Incyte Corporation $13,339.80 12/24/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547614
Principal investigator 1 Genentech, Inc. $405.00 12/19/2025 Non-covered Recipient Entity
RESEARCH PHYSICIANS NETWORK LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211643130
Principal investigator 1 ModernaTX, Inc. $17,184.96 12/19/2025 Non-covered Recipient Entity
LINQ RESEARCH LLC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252997787
Principal investigator 1 ModernaTX, Inc. $5,148.00 12/19/2025 Non-covered Recipient Entity
LINQ RESEARCH LLC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252997791
Principal investigator 1 Genentech, Inc. $5,500.00 12/17/2025 Non-covered Recipient Entity
RESEARCH PHYSICIANS NETWORK LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211643126
Principal investigator 1 Incyte Corporation $155.66 12/11/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547618
Principal investigator 1 Incyte Corporation $20.74 12/11/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547622
Principal investigator 1 Merck Sharp & Dohme LLC $27,592.00 11/24/2025 Non-covered Recipient Entity
LinQ Research
A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression No dispute reported 06/30/2026 1232929435
Principal investigator 1 Incyte Corporation $181.62 11/13/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547607
Principal investigator 1 Incyte Corporation $59.68 11/10/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547628
Principal investigator 1 Incyte Corporation $129.77 11/10/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547632
Principal investigator 1 Incyte Corporation $183.20 11/10/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547638
Principal investigator 1 Incyte Corporation $15.76 11/10/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547644
Principal investigator 1 Incyte Corporation $15.76 11/10/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547654
Principal investigator 1 Incyte Corporation $15.76 11/10/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547661
Principal investigator 1 Incyte Corporation $15.76 11/10/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547667
Principal investigator 1 Incyte Corporation $74.04 11/10/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547674
Principal investigator 1 Incyte Corporation $149.28 11/10/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547681
Principal investigator 1 Incyte Corporation $177.98 11/10/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547688
Principal investigator 1 Incyte Corporation $3.60 11/10/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547695
Principal investigator 1 Incyte Corporation $18.64 11/10/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547701
Principal investigator 1 Incyte Corporation $9.72 11/10/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547707
Principal investigator 1 Vanda Pharmaceuticals Inc. $1,500.00 10/22/2025 Non-covered Recipient Entity
LINQ RESEARCH LLC
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness No dispute reported 06/30/2026 1232946670
Principal investigator 1 Vanda Pharmaceuticals Inc. $2,900.00 10/22/2025 Non-covered Recipient Entity
LINQ RESEARCH LLC
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness No dispute reported 06/30/2026 1232946674
Principal investigator 1 AstraZeneca Pharmaceuticals LP $15,500.00 10/08/2025 Non-covered Recipient Entity
LINQ RESEARCH LLC
A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared with BDA Delivered by MDI HFA in Participants with Asthma No dispute reported 06/30/2026 1185554903
Principal investigator 1 AstraZeneca Pharmaceuticals LP $31,702.68 10/08/2025 Non-covered Recipient Entity
LINQ RESEARCH LLC
A Multicentre, Parallel-group, Phase IIb, Randomised, Double blind, Placebo-controlled, 4-Arm, 24-Week Study to Evaluate the Efficacy and Safety of AZD6793 Tablets in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PRESTO) No dispute reported 06/30/2026 1185554917
Principal investigator 1 Genentech, Inc. $3,336.00 09/24/2025 Non-covered Recipient Entity
RESEARCH PHYSICIANS NETWORK LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211643101
Principal investigator 1 ModernaTX, Inc. $37,402.56 08/28/2025 Non-covered Recipient Entity
LINQ RESEARCH LLC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252997789
Principal investigator 1 AstraZeneca Pharmaceuticals LP $15,200.00 08/20/2025 Non-covered Recipient Entity
LINQ RESEARCH LLC
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event No dispute reported 06/30/2026 1185554915
Principal investigator 1 ABBVIE INC. $1,358.00 08/05/2025 Non-covered Recipient Entity
LINQ RESEARCH LLC
A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine No dispute reported 06/30/2026 1202501708
Principal investigator 1 AstraZeneca Pharmaceuticals LP $139,994.56 07/11/2025 Non-covered Recipient Entity
LINQ RESEARCH LLC
a phase III,randomised,double blind,placebo controlled,event driven study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure No dispute reported 06/30/2026 1185554901
Principal investigator 1 Genentech, Inc. $55,440.00 07/11/2025 Non-covered Recipient Entity
RESEARCH PHYSICIANS NETWORK LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211643072
Principal investigator 1 Incyte Corporation $11.88 07/09/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547524
Principal investigator 1 Incyte Corporation $119.36 07/09/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547529
Principal investigator 1 Incyte Corporation $31.52 07/09/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547538
Principal investigator 1 Incyte Corporation $148.85 07/09/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547544
Principal investigator 1 Incyte Corporation $7.20 07/09/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547550
Principal investigator 1 Incyte Corporation $98.72 07/09/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547555
Principal investigator 1 Incyte Corporation $13.98 07/09/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547561
Principal investigator 1 Incyte Corporation $123.26 07/09/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547567
Principal investigator 1 Incyte Corporation $97.08 07/09/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547571
Principal investigator 1 Incyte Corporation $129.77 07/09/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547576
Principal investigator 1 Incyte Corporation $149.28 07/09/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547581
Principal investigator 1 Incyte Corporation $31.52 07/09/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547588
Principal investigator 1 Incyte Corporation $31.52 07/09/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547596
Principal investigator 1 Incyte Corporation $31.52 07/09/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547601
Principal investigator 1 Vanda Pharmaceuticals Inc. $5,800.00 07/03/2025 Non-covered Recipient Entity
LINQ RESEARCH LLC
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness No dispute reported 06/30/2026 1232945718
Principal investigator 1 ABBVIE INC. $200.00 07/02/2025 Non-covered Recipient Entity
LINQ RESEARCH LLC
A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine No dispute reported 06/30/2026 1202494579
Principal investigator 1 ABBVIE INC. $1,514.00 07/02/2025 Non-covered Recipient Entity
LINQ RESEARCH LLC
A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine No dispute reported 06/30/2026 1202494581
Principal investigator 1 Genentech, Inc. $400.00 07/02/2025 Non-covered Recipient Entity
RESEARCH PHYSICIANS NETWORK LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211643069
Principal investigator 1 Incyte Corporation $12.12 06/09/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547515
Principal investigator 1 Incyte Corporation $94.94 06/09/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547518
Principal investigator 1 AstraZeneca UK Limited $24,567.00 06/04/2025 Non-covered Recipient Entity
WCG IRB LLC
Phase 2b Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Dose-Ranging Study to Assess the Efficacy, Safety, and Tolerability of AZD2373 in Participants with APOL1-Mediated Kidney Disease (APPRECIATE) No dispute reported 06/30/2026 1185554919
Principal investigator 1 Genentech, Inc. $1,400.00 05/30/2025 Non-covered Recipient Entity
RESEARCH PHYSICIANS NETWORK LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211642993
Principal investigator 1 Genentech, Inc. $1,107.00 05/23/2025 Non-covered Recipient Entity
RESEARCH PHYSICIANS NETWORK LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211642998
Principal investigator 1 Genentech, Inc. $800.00 05/14/2025 Non-covered Recipient Entity
RESEARCH PHYSICIANS NETWORK LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211642930
Principal investigator 1 AstraZeneca Pharmaceuticals LP $295,818.44 05/07/2025 Non-covered Recipient Entity
LINQ RESEARCH LLC
a phase third,randomised,double blind,placebo controlled,eventdriven study to evaluate the effect of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on the risk of incident heart failure and cardiovascular death in participants with increased risk of reveloping heart failure No dispute reported 06/30/2026 1185554911
Principal investigator 1 ModernaTX, Inc. $12,916.80 05/05/2025 Non-covered Recipient Entity
LINQ RESEARCH LLC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252997785
Principal investigator 1 Genentech, Inc. $160.00 04/30/2025 Non-covered Recipient Entity
RESEARCH PHYSICIANS NETWORK LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211642955
Principal investigator 1 ModernaTX, Inc. $3,032.64 04/28/2025 Non-covered Recipient Entity
LINQ RESEARCH LLC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252997793
Principal investigator 1 Genentech, Inc. $101,952.00 04/25/2025 Non-covered Recipient Entity
RESEARCH PHYSICIANS NETWORK LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211643029
Principal investigator 1 Vanda Pharmaceuticals Inc. $14,600.00 04/23/2025 Non-covered Recipient Entity
LINQ RESEARCH LLC
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness No dispute reported 06/30/2026 1232945204
Principal investigator 1 Vanda Pharmaceuticals Inc. $122.23 04/23/2025 Non-covered Recipient Entity
LINQ RESEARCH LLC
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness No dispute reported 06/30/2026 1232945207
Principal investigator 1 ABBVIE INC. $2,602.00 04/03/2025 Non-covered Recipient Entity
LINQ RESEARCH LLC
A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine No dispute reported 06/30/2026 1202468778
Principal investigator 1 AstraZeneca Pharmaceuticals LP $234,241.65 03/26/2025 Non-covered Recipient Entity
LINQ RESEARCH LLC
Levante A Phase 2b Randomised Double Blind Placebo Controlled Dose Range Finding Study to Assess Efficacy and Safety of Multiple Dose Levels of Inhaled AZD8630 No dispute reported 06/30/2026 1185554907
Principal investigator 1 Incyte Corporation $65.24 03/10/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547416
Principal investigator 1 Incyte Corporation $74.04 03/10/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547427
Principal investigator 1 Incyte Corporation $23.64 03/10/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547435
Principal investigator 1 Incyte Corporation $23.64 03/10/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547439
Principal investigator 1 Incyte Corporation $59.68 03/10/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547467
Principal investigator 1 Incyte Corporation $23.64 03/10/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547489
Principal investigator 1 Incyte Corporation $23.64 03/10/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547495
Principal investigator 1 ABBVIE INC. $1,514.00 03/06/2025 Non-covered Recipient Entity
LINQ RESEARCH LLC
A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine No dispute reported 06/30/2026 1202456489
Principal investigator 1 Genentech, Inc. $763.00 02/26/2025 Non-covered Recipient Entity
RESEARCH PHYSICIANS NETWORK LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211642810
Principal investigator 1 Vanda Pharmaceuticals Inc. $14,600.00 02/25/2025 Non-covered Recipient Entity
LINQ RESEARCH LLC
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness No dispute reported 06/30/2026 1232944836
Principal investigator 1 Genentech, Inc. $763.00 02/19/2025 Non-covered Recipient Entity
RESEARCH PHYSICIANS NETWORK LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211642867
Principal investigator 1 ABBVIE INC. $1,358.00 02/05/2025 Non-covered Recipient Entity
LINQ RESEARCH LLC
A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine No dispute reported 06/30/2026 1202445156
Principal investigator 1 ModernaTX, Inc. $32,348.16 02/05/2025 Non-covered Recipient Entity
LINQ RESEARCH LLC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252997795
Principal investigator 1 Genentech, Inc. $763.00 01/31/2025 Non-covered Recipient Entity
RESEARCH PHYSICIANS NETWORK LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211642848
Principal investigator 1 ModernaTX, Inc. $4,043.52 01/27/2025 Non-covered Recipient Entity
LINQ RESEARCH LLC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252997797
Principal investigator 1 AstraZeneca Pharmaceuticals LP $131,372.45 01/24/2025 Non-covered Recipient Entity
LINQ RESEARCH LLC
A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of Zibotentan/Dapagliflozin FDC Compared to Dapagliflozin Alone in Participants with Chronic Kidney Disease and High Proteinuria No dispute reported 06/30/2026 1185554913
Principal investigator 1 Vanda Pharmaceuticals Inc. $9,100.00 01/22/2025 Non-covered Recipient Entity
LINQ RESEARCH LLC
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness No dispute reported 06/30/2026 1232944585
Principal investigator 1 Vanda Pharmaceuticals Inc. $2,900.00 01/22/2025 Non-covered Recipient Entity
LINQ RESEARCH LLC
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness No dispute reported 06/30/2026 1232944589
Principal investigator 1 Incyte Corporation $8,503.20 01/16/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547710
Principal investigator 1 Incyte Corporation $5.40 01/09/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547245
Principal investigator 1 Incyte Corporation $60.58 01/09/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547250
Principal investigator 1 Incyte Corporation $6.60 01/09/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547256
Principal investigator 1 Incyte Corporation $279.90 01/09/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547262
Principal investigator 1 Incyte Corporation $7.50 01/09/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547267
Principal investigator 1 Incyte Corporation $10.20 01/09/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547272
Principal investigator 1 Incyte Corporation $48.48 01/09/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547278
Principal investigator 1 Incyte Corporation $251.90 01/09/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547284
Principal investigator 1 Incyte Corporation $17.28 01/09/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547286
Principal investigator 1 Incyte Corporation $111.96 01/09/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547294
Principal investigator 1 Incyte Corporation $5.40 01/09/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547299
Principal investigator 1 Incyte Corporation $6.48 01/09/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547304
Principal investigator 1 Incyte Corporation $31.52 01/09/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547311
Principal investigator 1 Incyte Corporation $226.52 01/09/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547320
Principal investigator 1 Incyte Corporation $13.98 01/09/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547328
Principal investigator 1 Incyte Corporation $13.98 01/09/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547337
Principal investigator 1 Incyte Corporation $167.94 01/09/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547341
Principal investigator 1 Incyte Corporation $27.96 01/09/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547348
Principal investigator 1 Incyte Corporation $10.80 01/09/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547352
Principal investigator 1 Incyte Corporation $2.16 01/09/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547359
Principal investigator 1 Incyte Corporation $98.72 01/09/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547365
Principal investigator 1 Incyte Corporation $31.52 01/09/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547371
Principal investigator 1 Incyte Corporation $31.52 01/09/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547376
Principal investigator 1 Incyte Corporation $123.26 01/09/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547381
Principal investigator 1 Incyte Corporation $52.48 01/09/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547388
Principal investigator 1 Incyte Corporation $119.36 01/09/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547394
Principal investigator 1 Incyte Corporation $74.64 01/09/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547399
Principal investigator 1 Incyte Corporation $1.20 01/09/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547406
Principal investigator 1 Incyte Corporation $1.20 01/09/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547411
Principal investigator 1 Incyte Corporation $129.77 01/09/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547421
Principal investigator 1 Incyte Corporation $18.66 01/09/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547444
Principal investigator 1 Incyte Corporation $4.66 01/09/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547450
Principal investigator 1 Incyte Corporation $9.18 01/09/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547457
Principal investigator 1 Incyte Corporation $12.96 01/09/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547461
Principal investigator 1 Incyte Corporation $4.32 01/09/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547473
Principal investigator 1 Incyte Corporation $31.52 01/09/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547477
Principal investigator 1 Incyte Corporation $298.56 01/09/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547482
Principal investigator 1 Incyte Corporation $4.20 01/09/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547499
Principal investigator 1 Incyte Corporation $13.98 01/09/2025 Non-covered Recipient Entity
LINQ RESEARCH, LLC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240547508
Principal investigator 1 AstraZeneca Pharmaceuticals LP $105,565.81 01/03/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler No dispute reported 06/30/2026 1185554905
Principal investigator 1 AstraZeneca Pharmaceuticals LP $71,622.15 01/03/2025 Non-covered Recipient Entity
LINQ RESEARCH LLC
A Phase III Randomised Doubleblind Study to Evaluate the Effect of Balcinrenone Dapagliflozin Compared with Dapagliflozin on the Risk of Heart Failure Events and Cardiovascular Death in Patients with Heart Failure and Impaired Kidney Function No dispute reported 06/30/2026 1185554909
Principal investigator 1 ABBVIE INC. $2,758.00 01/02/2025 Non-covered Recipient Entity
LINQ RESEARCH LLC
A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine No dispute reported 06/30/2026 1202434965